Drug Approval | October 18, 2023
Biocon will be responsible for obtaining regulatory approval for Liraglutide, and thereafter, for the manufacture and supply of the product in the Canadian market
The company had submitted a comprehensive Corrective and Preventive Action (CAPA) plan in September 2022
The centralized marketing authorization granted by the EC is valid in all EU Member States as well as in the European Economic Area (EEA) countries Iceland, Liechtenstein and Norway
Bains has stepped down from his role on the Biocon Board as an Independent Director with immediate effect
Biocon Biologics recently acquired the global biosimilars business of its long-term partner Viatris
The facility has a potential for capacity expansion up to 2 billion tablets/capsules per year
Marks the World Head & Neck Cancer Day at the OCTF Conference
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)